Thyme Therapeutics is building a new oncology biosimilars model designed to bring lower-cost medicines to market and and reduce the cost of cancer via more stable, lower pricing.

Cancer treatments are advancing rapidly, improving outcomes, and transforming patients' lives. But rising costs are putting growing pressure on patients and the healthcare system. Biosimilars offer a path to ease that pressure, delivering the same high-quality treatment at a lower cost, just as major biologics approach loss of exclusivity.

• ~50% of oncology spend in the U.S. is on drugs¹

• 20%+ of that drug spend is on medicines expected to have biosimilar alternatives by 2029²

Thyme Therapeutics partners with manufacturers to bring durable and predictable pricing to biosimilars, then we work with health plans, oncology practices, and health systems to make those drugs easier to adopt and sustain.

Biosimilars can meaningfully expand low-cost treatment options. But unstable, unpredictable pricing has limited their ability to fully deliver on that promise.

Our goal is simple: help more of the value created by biosimilars benefit patients and the healthcare system as a whole.